An example that I found interesting and insightful:
ASH 2023 | Thromboembolic event rates in patients with PV: a real-world analysis
Andrew Kuykendall • 27 Nov 2023 ASH 2023 Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases
Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, comments on a real-world analysis investigating the rate of thromboembolic events (TEs) in patients with polycythemia vera (PV). This analysis included over 20,000 US patients and took into account TEs prior to and following PV diagnosis. Dr Kuykendall emphasizes that, although patients with prior history of TE were at greatest risk of another event, TE risk is high in all [MPN patients, even those considered ‘low-risk’. Clinicians must continue to focus on decreasing TE risk as the primary treatment goal in PV. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.